Logo-jpe
Submitted: 27 Aug 2021
Accepted: 04 Oct 2021
ePublished: 25 Oct 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Prev Epidemiol. 2022;7(1): e02.
doi: 10.34172/jpe.2022.02
  Abstract View: 70
  PDF Download: 36

Original

Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial

Somaieh Ashrafi 1 ORCID logo, Seyyed Mohammad Ghaffari 1 ORCID logo, Hatam Boostani 1 ORCID logo, Somaieh Raz 2 ORCID logo, Negar Ebadi 3 ORCID logo, Zahra Ashrafi 4 ORCID logo, Pedram Nazari 4* ORCID logo

1 Golestan Hospital, Psychiatry Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Internal Medicine Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Institute for Cognitive Science Studies, Tehran, Iran
4 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Correspondence to: Pedram Nazari, Email: nazari.p@ ajums.ac.ir

Abstract

Introduction: Statins such as simvastatin are recently introduced as agents that may have beneficial effects in schizophrenia regarding their prominent anti-inflammatory properties.

Objectives: This study was designed to evaluate the effects of simvastatin on schizophrenia symptoms.

Patients and Methods: In a double-blinded randomized clinical trial, 40 hospitalized schizophrenia patients (according to the DSM-IV-TR criteria) were studied for 6 weeks. One group of the patients (n=20) received simvastatin (with the dose of 40 mg/d) and the other group received (n=20) placebo. The patients were evaluated by the Positive and Negative Syndrome Scale (PANSS) for schizophrenia symptoms. Data were analyzed with mixed model repeated measure ANOVA, t test, and χ2 test or Fischer’s exact test by SPSS software. The significant cutoff was considered at P<0.05.

Results: The mean age of the patients was 34.05±9.74 years and 50% of them were men. There was not a significant difference between the two groups regarding negative symptoms reduction.

Conclusion: Our study demonstrated that adding simvastatin on atypical antipsychotic treatment had no significant beneficial effects on the negative and positive symptoms in patients with schizophrenia disorder.

Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT2017052034046N1; https://en.irct.ir/trial/26134, ethical code; ETH-457).

Keywords: Schizophrenia, Negative symptoms, Simvastatin
Citation: Ashrafi S, Ghaffari SM, Boostani H, Raz S, Ebadi N, Ashrafi Z, Nazari P. Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial. J Prev Epidemiol. 2022;7(1):e02. doi: 10.34172/jpe.2022.02.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 71

Your browser does not support the canvas element.


PDF Download: 36

Your browser does not support the canvas element.